Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Biogen
since
auto-detected in 3 stories
80 days ago
page 1 of 1